Exscientia plc (NASDAQ:EXAI) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET

Company Participants

Sara Sherman - Vice President of Investor Relations

Andrew Hopkins - Chief Executive Officer

Mike Krams - Chief Quantitative Medicine Officer

Nikolaus Krall - EVP, Precision Medicine

Ben Taylor - CFO and Chief Strategy Officer

Dave Hallett - Chief Scientific Officer

Conference Call Participants

Alec Stranahan - Bank of America

Gaurav Goparaju - Berenberg Capital Markets

Vikram Purohit - Morgan Stanley

Operator

Hello, everyone. My name is Abby and I'll be your conference operator today. At this time, I'd like to welcome everyone to Exscientia's Business Update Call for the Second Quarter 2023. [Operator Instructions] Thank you.

And at this time, I'd like to introduce Sara Sherman, Vice President of Investor Relations. Sara, you may begin.

Sara Sherman

Thank you, operator. A press release and 6-K were issued this morning with our first half and second quarter 2023 financial results and business update. These documents can be found on our website at www.investors.exscientia.ai, along with the presentation for today's webcast.

Before we begin, I'd like to remind you that we may make forward-looking statements on our call. These may include statements about our projected growth, revenue, business models, preclinical and clinical results and business performance. Actual results may differ materially from those indicated by these statements. Unless required by law, Exscientia does not undertake any obligation to update these statements regarding the future or to confirm these statements in relation to actual results.

On today's call, I'm joined by Professor Andrew Hopkins, Chief Executive Officer; Dr. Mike Krams, Chief Quantitative Medicine Officer; Dr. Nikolaus Krall, EVP, Precision Medicine; and Ben Taylor, CFO and Chief Strategy Officer. Dr. Dave Hallett, Chief Scientific Officer, will also be available for the Q&A session.

And with that, I will now turn the call over to Andrew.

Andrew Hopkins

Thank you, Sara. The first half of 2023 has seen a major step forward in our development pipeline with four compounds progressing in clinical trials. We recently dosed the first patients in both ELUCIDATE, our Phase 1/2 trial of our CDK7 inhibitor GTAEXS617 partnered with GT Apeiron and IGNITE a Phase 1/2 trial of our A2A receptor antagonist EXS21546. Earlier this year, two partnered compounds, a PKC-theta inhibitor in-licensed by Bristol-Myers Squibb for immunology and a bispecific psychiatric compound designed for Sumitomo Pharma also started Phase 1 clinical trials.

We've also made significant progress in other parts of our pipeline. Notably, we initiated a prospective observational study called EXCYTE-1, evaluating the predictive power of our precision medicine platform in ovarian cancer. The study has the potential to validate further our platform for wider use across a variety of solid tumors.